EP Patent

EP2211842B1 — An inhalable dry powder formulation comprising glp-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration

Assigned to Mannkind Corp · Expires 2015-08-12 · 11y expired

What this patent protects

Patent listed against Remodulin.

Drugs covered by this patent

Patent Metadata

Patent number
EP2211842B1
Jurisdiction
EP
Classification
—
Expires
2015-08-12
Drug substance claim
No
Drug product claim
No
Assignee
Mannkind Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.